Asklepios Group: Solid third quarter of 2025 – successful placement of Social Schuldschein loan strengthens financing basis

In the first nine months of 2025, the Asklepios Group put in an overall solid operating performance. Despite healthcare policy challenges and a difficult economic environment, the number of patients was once again increased and consolidated profit was improved. Parallel to that, the Group has also given a significant boost to its sustainable financing.

From January to September 2025, the Group’s healthcare facilities treated a total of 2,915,971 patients (9M 2024: 2,742,439) – an increase of roughly 6.3% over the previous year. While moderate growth in patient numbers was observed in the inpatient area, the overall trend was mainly driven by growth in the outpatient area. 

Consolidated revenue totalled EUR 4,770.1 million (9M 2024: EUR 4,350.8 million) in the first nine months, which is an increase of 9.6%. Consolidated net income after tax (EAT) for the period increased to EUR 114.5 million (9M 2024: EUR 88.2 million). Total investments over the reporting period were EUR 302.8 million (9M 2024: EUR 232.4 million).

On 29 October 2025, the Asklepios Group successfully placed a Social Schuldschein loan in the amount of EUR 600.0 million. It was issued under the Social Finance Framework for early refinancing of maturities for the years 2025 to 2027 and was subscribed by both existing and international investors. With maturities of 3, 5, 7 and 10 years as well as a 52% share of international investors, the capital base was further diversified.

Hafid Rifi, CFO of the Asklepios Group, noted:

“The new Social Schuldschein loan allows us to further develop the strategy of our finance portfolio and to actively manage our maturities. What is especially encouraging is the strong interest shown by international investors, clearly underscoring the trust in our sustainable course.“